Lennart Dreyer has been CarryGene's Executive Vice President and Chief Business Officer since 2019. He has been Dean and CEO of IHM Business School, as well as a former visiting professor at Tsinghua University Beijing. Dreyer has also been a management consultant at Baine, Deloitte and SIAR/Bossard, and later CEO of Business Research Group Ltd, with consulting activities in Asia and Europe. Other assignments: Business Research AB

Greg Batcheller has an extensive background as CEO and Chairman of the Board of several life science companies such as Xintela AB, Saga Diagnostics AB, ImmuneBiotech AB and Immodulate Pharma AB. Greg has worked with the Business Research Group in Asia and Europe since 2014 as a Partner and Senior Advisor. Other assignments: Saga DX Inc., Edvince Aktiebolag, Intellego Technologies AB

Experienced biotechnology entrepreneur with more than 25 years of experience as an executive, director, investor and advisor in the biotechnology industry. Alistair also is the Co-founder, President and CEO at viDA Therapeutics Inc.

Co-founder and Managing Partner of SynPloid Biotek, LLC, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA) and currently known as CG Bioengineering. Dr. Greene has a scientific background in synthetic chromosome biology. She served as Manager Intellectual Property and Business Development, Chromos Molecular Systems, Inc. (Vancouver, BC Canada). She previously held an academic appointment as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine. Dr. Greene earned her PhD at the University of Iowa (USA) and did post-doctoral work at the National Institutes of Health.

Jan Nilsson holds a Master of Arts degree from the University of Gothenburg and an MBA from Uppsala University. Jan has long and broad experience in both large pharmaceutical and biotech companies. He has been active in several different therapeutic areas within the pharmaceutical industry. He has in addition to participating in the drug development process also had key roles in the launch, sales, and marketing of established international brands. Jan is currently Chairman of the Board of CCRM Nordic AB (svb) and Urbicum Ledningskonsult AB.

Lennart Dreyer has been CarryGene's Executive Vice President and Chief Business Officer since 2019. He has been Dean and CEO of IHM Business School, as well as a former visiting professor at Tsinghua University Beijing. Dreyer has also been a management consultant at Baine, Deloitte and SIAR/Bossard, and later CEO of Business Research Group Ltd, with consulting activities in Asia and Europe. Other assignments: Business Research AB

Greg Batcheller has an extensive background as CEO and Chairman of the Board of several life science companies such as Xintela AB, Saga Diagnostics AB, ImmuneBiotech AB and Immodulate Pharma AB. Greg has worked with the Business Research Group in Asia and Europe since 2014 as a Partner and Senior Advisor. Other assignments: Saga DX Inc., Edvince Aktiebolag, Intellego Technologies AB

Dr. Sven Rohmann's unique combination of scientific, pharma/biotech, and venture capital knowledge, an extensive network of contacts among healthcare providers and academic and government research administrators, a thorough knowledge of global research and development and EMA/FDA regulatory policies, and a significant experience in M&A and partnerships, make him one of the leading experts in value-driven business development. Previous assignments include Merck-Serono, Novartis Pharma, Ganymed Pharmaceuticals, Biontech AG, Oasmia and Immunicum. Other assignments: Hervolution ApS, ISR Holding AB, Oryx Alpha GmbH, Asclepiceutical AI

Education and previous work experience: Master of Science in Business and Economics. Auditor at EY and Management Consultant and partner at several large consulting companies such as EY, Capgemini and Implement Consulting Group. Now works as CEO of TLA Targeted Immunotherapies AB. Certified board member from the board academy. Other assignments: Tinnovate AB, ITH Immunotherapies Holding AB